Influence of renin–angiotensin system on serum parathyroid hormone levels in uremic patients
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
Introduction The aim of this study was to investigate the factors influencing serum parathyroid (PTH) levels, including medications for treating chronic kidney disease-mineral and bone metabolism disorder (CKD-MBD) in patients with end-stage renal disease. Methods We enrolled 1,076 patients in nine Japanese facilities who had begun hemodialysis (HD) due to ESRD. We investigated the relationships between intact PTH (iPTH) levels and clinical parameters and medications just prior to beginning HD. Results Significant decreases in serum iPTH levels were seen in males, in the presence of diabetes mellitus (DM), and with administration of renin-angiotensin system inhibitors (RASIs). Significant correlations were found between serum calcium and iPTH levels. In the patients administered RASIs, there was a significant decrease in serum iPTH levels with DM, male gender, and administration of active vitamin D sterols (VDs) compared with those not administered RASIs, although serum-corrected calcium levels were not different. Multiple regression analysis found gender, age, presence of DM, and serum calcium and phosphate levels to be significant contributing factors. In addition, administration of angiotensin II receptor blockers (ARBs) may also be a contributing factor to iPTH levels at the beginning HD (p = 0.050). Conclusions In this study, serum iPTH levels were related to administration of ARBs besides gender, age, the presence of DM and serum calcium levels. Our study suggests that…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
Massry, S. G., Coburn, J. W., Chertow, G. M., Hruska, K. A., Langman, C. B., Malluche, H. H., Martin, K. J., McCann, L. M., McCarthy, J. T., Moe, S. M., et al. (2003) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 2,527
MacLeod, A. M. (2009) · Kidney International · Cited by 2,219
1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system
Li, Y. C., Kong, J., Wei, M., Chen, Z.-F., Liu, S. Q., & Cao, L.-P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215219 · Cited by 1,625 · cited 1×
“The physiological functions of vitamin D in relation to the RA system were clarified by a report that calcitriol suppresses renin activity not via Ca, but via the vitamin D receptor, so vitamin D is a negative regulator in renin biosynthesis [18].”
BackgroundLevin, A., Bakris, G. L., Molitch, M., Smulders, M., Tian, J., Williams, L. A., & Andress, D. L. (2007) · Kidney International · doi:10.1038/sj.ki.5002009 · Cited by 1,513 · cited 1×
“There is a compensatory increase in the serum level of iPTH that exceeds the normal range in CKD stage 3 (estimated glomerular filtration rate 30–59 ml/min), regardless of whether serum P and Ca levels remain within the normal range [1, 2].”
BackgroundK/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.
(2003) · PubMed · Cited by 1,372
The parathyroid is a target organ for FGF23 in rats
Ben-Dov, I. Z., Galitzer, H., Lavi-Moshayoff, V., Goetz, R., Kuro-o, M., Mohammadi, M., Sirkis, R., Naveh-Many, T., & Silver, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32409 · Cited by 951 · cited 1×
“It has been suggested that circulating levels of FGF23 increase in the early stages of CKD [3], inhibiting 25-hydroxyvitamin D-1a-hydroxylase, resulting in decreased circulating 1,25D levels and increased serum PTH levels [4].”
BackgroundWood, R. J., Tchack, L., & Taparia, S. (2001) · BMC Physiology · doi:10.1186/1472-6793-1-11 · Cited by 849
Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053107 · Cited by 710 · cited 1×
“We demonstrated significant decreases in iPTH levels with RASI administration, which has been an established renoprotective therapy for 10 years, with their beneficial antiproteinuric effects that delay progression of renal dysfunction [13, 14].”
Background
Cited by
Tomaschitz, A., Ritz, E., Pieske, B., Rus-Machan, J., Kienreich, K., Verheyen, N., Gaksch, M., Grübler, M., Fahrleitner-Pammer, A., Mrak, P., et al. (2014) · Metabolism · doi:10.1016/j.metabol.2013.08.016 · Cited by 166
“documented in hemodialysis Japanese patients a decline of iPTH levels in parallel with the administration of RAS inhibitors independent of serum calcium levels [92].”
BackgroundThe renin–angiotensin–aldosterone system and calcium-regulatory hormones
Vaidya, A., Brown, J. M., & Williams, J. S. (2015) · Journal of Human Hypertension · doi:10.1038/jhh.2014.125 · Cited by 93
Brown, J. M., Williams, J. S., Luther, J. M., Garg, R., Garza, A. E., Pojoga, L. H., Ruan, D. T., Williams, G. H., Adler, G. K., & Vaidya, A. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.01910 · Cited by 88
“Calcium,1,2 vitamin D,3–9 and parathyroid hormone (PTH)10–12 have been implicated in regulating the renin–angiotensin–aldosterone system (RAAS), and the RAAS, in turn, has been implicated in regulating these calcium- regulatory hormones.13–16 In particular, recent observational studies in individuals with primary hype…”
BackgroundInfluentialThe Interplay Between the Renin-Angiotensin-Aldosterone System and Parathyroid Hormone
Zheng, M.-H., Li, F., Xu, F., Lin, X., Wang, Y., Xu, Q.-S., Guo, B., & Yuan, L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00539 · Cited by 74
“The use of ARB also significantly reduces the level of PTH (76, 87, 88), although this conclusion remains controversial.”
BackgroundBrown, J., de Boer, I. H., Robinson-Cohen, C., Siscovick, D. S., Kestenbaum, B., Allison, M., & Vaidya, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3949 · Cited by 71
Metadata
- Authors
- Koiwa, F., Komukai, D., Hirose, M., Yoshimura, A., Ando, R., Sakaguchi, T., Komatsu, Y., Shinoda, T., Inaguma, D., Joki, N., Nishida, H., Ikeda, M., & Shigematsu, T.
- Affiliations
- SHOWA Medical University Fujigaoka Hospital (JP)
- Start Treatment & Recovery Centers (US)
- Corresponding author
- Koiwa, Fumihiko
- ORCID
- Venue
- Clinical and Experimental Nephrology
- Published
- 2011-09-14
- Volume
- 16
- Issue
- 1
- Pages
- 130-135
- ISSN
- 1342-1751 (ISSN-L)
- 1437-7799
- OpenAlex
- W1980709686
- Cited by
- 17
- References
- 26
- Citations by year
- 2026: 1 · 2022: 2 · 2020: 2 · 2017: 1 · 2015: 3 · 2014: 5 · 2013: 3
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Clinical and Experimental Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Nephrology › Renal function and acid-base balance
- Keywords
- renin-angiotensin system, parathyroid hormone, intact PTH, end-stage renal disease, hemodialysis initiation, renin-angiotensin system inhibitors, angiotensin receptor blockers, chronic kidney disease-mineral and bone disorder, diabetes mellitus, serum calcium, phosphate, uremia
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Calcium, Female, Renal Dialysis, Humans, Kidney Failure, Chronic, Male, Middle Aged, Parathyroid Hormone, Renin-Angiotensin System, Uremia, Vitamin D, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Influence of renin–angiotensin system on serum parathyroid hormone levels in uremic patients. https://app.cochat.ai/papers/10.1007/s10157-011-0534-x
- The paper
- Koiwa, F., Komukai, D., Hirose, M., Yoshimura, A., Ando, R., Sakaguchi, T., Komatsu, Y., Shinoda, T., Inaguma, D., Joki, N., Nishida, H., Ikeda, M., & Shigematsu, T. (2012). Influence of renin–angiotensin system on serum parathyroid hormone levels in uremic patients. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-011-0534-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.